Trial NCT04397562
Publication Lomakin N V, Inflamm Res, 2021
Primary outcome on the report: Overall mortality initial), ≥2-category improvement in clinical status relative to baseline on the 7-category ordinal scale or reaching the clinical status of categories 1 or 2 on Day 14 (amended)

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.